texas health science center

(University of Texas Health Science Center at Houston) NanoMedical Systems Inc., an Austin-based startup cofounded by Mauro Ferrari, Ph.D., of the University of Texas Health Science Center at Houston, to improve the effectiveness of anti-cancer agents and other medications, has received a record $3.5 million Commercialization Award through the Texas Emerging Technology Fund.

(University of Texas Health Science Center at Houston) Two clones of highly antibiotic-resistant organism strains, which previously had only been identified in the United States, are now causing serious sickness and death in several Colombian cities including the capital Bogotá, say researchers at The University of Texas Medical School at Houston.

The study, done in collaboration with Universidad El Bosque in Bogota, is presented in a research letter published in the Nov. 13 issue of the New England Journal of Medicine.

(University of Texas Health Science Center at Houston) Human immunodeficiency virus researchers at The University of Texas Medical School at Houston believe they have uncovered the Achilles heel in the armor of the virus that continues to kill millions.

(University of Texas at San Antonio) Researchers at the University of Texas at San Antonio South Texas Center for Emerging Infectious Diseases and the University of Texas Health Science Center at San Antonio have identified a cell type believed to play a role in controlling the early infectious process against Francisella tularensis, a respiratory pathogen and bioterrorism agent that is the cause of tularemia.

The findings will be released this week in a journal article in the Proceedings of the National Academy of Sciences.

(University of Texas Health Science Center at Houston) Researchers at the University of Texas School of Public Health have found that patients given a travelers' diarrhea vaccine were significantly less likely to suffer from clinically significant diarrhea than those who received placebo, according to a study published in this week's edition of the Lancet.

The patch-based vaccine is part of the Phase 2 study in conjunction with the Iomai Corp.

(University of Texas Health Science Center at Houston) Researchers at The University of Texas Medical School at Houston have identified family history as one reason why some people might be more susceptible to shingles, a severe skin condition.

At "Why I Sent It Is a Mystery - More About Avandia, Conflicts of Interest, and Confused Thinking" Roy Poses documents a response from a prominent biomedical researcher, Steven Haffner of the University of Texas Health Science Center at San Antonio, as to why he rather blatantly breached scientific reviewer's code of conduct.

This code of conduct is not a mystery and is quite explicit.